top of page

ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart

  • 3 minutes ago
  • 1 min read

CEO Aron Knickerbocker walks us through the data, which included a doublet regimen with aldesleukin and a triplet that also included nivolumab, and suggests that Aulos is planning to meet with FDA about a potential accelerated approval pathway for the therapy.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page